Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessing Tenapanor as a Treatment of CF-related Constipation.
Sponsor: Massachusetts General Hospital
Summary
Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. They will also complete three questionnaires, the PAC-SYM, PAC-QoL, and IBS-SSS, and daily diaries to characterize GI symptom burden and spontaneous bowel movement (SBM) frequency.
Official title: An Open-label, Single Center Study Assessing Tenapanor as a Non-CFTR-mediated Treatment of CF-related Constipation in People With CF.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2025-06-01
Completion Date
2027-06-30
Last Updated
2026-03-18
Healthy Volunteers
No
Conditions
Interventions
Tenapanor
CF patients with CFrC will ingest one 50 mg tablet of tenapanor twice daily for 4 weeks.
Locations (1)
Massachusetts General Hospital
Boston, Massachusetts, United States